Abstract 1197P
Background
Non-functioning, sporadic, G1-G2 pancreatic neuroendocrine tumors usually display an indolent course. Surgery is the first-choice treatment for localized tumors >2 cm. Unresectable or metastatic PanNETs expressing somatostatin receptors are treated with somatostatin analogs (SSAs). The PROMID and the CLARINET studies proved the SSA antiproliferative effect in advanced gastro-entero-pancreatic neuroendocrine tumors. The standard treatment for patients with PanNETs ≤2cm is active surveillance. Yet no evidence of the value of SSA treatment exist in such patient population.
Methods
We retrospectively collected data from 72 patients with sporadic non-functioning G1-G2 PanNETs≤2cm, 31 treated with somatostatin analogs and 41 underwent to active surveillance at our Institution. Median progression-free survival (mPFS) and response rate (RR) were analyzed in SSA group and AS group. Survival was described by the Kaplan-Meier method with Mantel-Haenszel log-rank test. Cox-regression analysis was used to assess, both singularly and collectively, the weight of clinically relevant covariates on survival outcomes. Statistical significance was declared at two-sided p<0.05.
Results
At a median follow-up of 53.7 months, the median progression free survival was not reached in the treatment group versus an estimated PFS of 85 months in the control group (HR 0.11, p = 0.01), with a rate of progression or death up to 21.9% in the active surveillance group. Further, in the group of patients treated with somatostatin analogs response rate was 16.1% with one complete response.
Conclusions
Our monocentric experience demonstrated a significant antiproliferative activity of somatostatin analogs in patients with sporadic, non-functionating G1-G2 PanNETs ≤2cm delaying tumor progression and distant spread in small lesions that sometimes may reveal an unpredictable aggressiveness.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1198P - Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
Presenter: Jonathan Strosberg
Session: Poster session 13
1199P - MAVERIC: Phase II randomized study of everolimus as maintenance therapy for metastatic neuroendocrine neoplasms (mNEN) with pulmonary or gastroenteropancreatic (GEP) origin. Results on behalf of the GOIRC
Presenter: Lorenzo Antonuzzo
Session: Poster session 13
1200P - A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial
Presenter: oOttavia Clemente
Session: Poster session 13
1201P - Evaluation of efficacy TEMCAP regiment as first-line or further line therapy in patients with advanced, unresectable, progressive GEP-NET. Real-world data
Presenter: Agnieszka Kolasinska-Cwikla
Session: Poster session 13
1202P - Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)
Presenter: Claudia von Arx
Session: Poster session 13